HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

Biochemical and Biophysical Research Communications

Volumn 318, Issue 3, 2004, Pages 719-725

  Yamamoto, Norio ^a   Yang, Rongge ^a   Yoshinaka, Yoshiyuki ^a   Amari, Shinji ^b   Nakano, Tatsuya ^c   Cinatl, Jindrich ^d   Rabenau, Holger ^d   Doerr, Hans Wilhelm ^d   Hunsmann, Gerhard ^e   Otaka, Akira ^f   Tamamura, Hirokazu ^f   Fujii, Nobutaka ^f   Yamamoto, Naoki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^e GERMAN PRIMATE CENTER   (Germany)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

Coronavirus; HIV protease inhibitor; Severe acute respiratory syndrome

Indexed keywords

ANTIVIRUS AGENT; ENFUVIRTIDE; FC 131; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; INDINAVIR; KYNOSTATIN 272; LOPINAVIR; N 36; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SC 34; STROMAL CELL DERIVED FACTOR 1; SULFATE; T 140; T 22; TC 14012; TE 14011; TN 14003; TYA 5; TYB 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG SCREENING; DRUG USE; EXPERIMENT; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELL; VIRION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; FLUORESCENT ANTIBODY TECHNIQUE; HIV PROTEASE INHIBITORS; LETHAL DOSE 50; NELFINAVIR; RITONAVIR; RNA, VIRAL; SARS VIRUS; TIME FACTORS; VERO CELLS; VIRUS REPLICATION;

CORONAVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SARS CORONAVIRUS;

EID: 2442545542     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.04.083     Document Type: Article

References (26)

1. Lee N., Hui D., Wu A., Chan P., Cameron P., Joynt G.M., Ahuja A., Yung M.Y., Leung C.B., To K.F., Lui S.F., Szeto C.C., Chung S., Sung J.J. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348:2003;1986-1994
2. S. M. Poutanen, D.E. Low, B. Henry, S. Finkelstein, D. Rose, K. Green, R. Tellier, R. Draker, D. Adachi, M. Ayers, A.K. Chan, D.M. Skowronski, I. Salit, A.E. Simor, A.S. Slutsky, P.W. Doyle, M. Krajden, M. Petric, R.C. Brunham, A.J. McGeer, C. National Microbiology Laboratory, T. Canadian Severe Acute Respiratory Syndrome Study, Identification of severe acute respiratory syndrome in Canada, N. Engl. J. Med. 348 (2003) 1995-2005
3. Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., Lam W.K., Seto W.H., Yam L.Y., Cheung T.M., Wong P.C., Lam B., Ip M.S., Chan J., Yuen K.Y., Lai K.N. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348:2003;1977-1985
4. WHO, in, 2003
5. Donnelly C.A., Ghani A.C., Leung G.M., Hedley A.J., Fraser C., Riley S., Abu-Raddad L.J., Ho L.M., Thach T.Q., Chau P., Chan K.P., Lam T.H., Tse L.Y., Tsang T., Liu S.H., Kong J.H., Lau E.M., Ferguson N.M., Anderson R.M. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet. 361:2003;1761-1766
6. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:2003;1967-1976
7. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J., Group S.W. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348:2003;1953-1966
8. Fouchier R.A., Kuiken T., Schutten M., van Amerongen G., van Doornum G.J., van den Hoogen B.G., Peiris M., Lim W., Stohr K., Osterhaus A.D. Aetiology: Koch's postulates fulfilled for SARS virus. Nature. 423:2003;240
9. Gao W., Tamin A., Soloff A., D'Aiuto L., Nwanegbo E., Robbins P.D., Bellini W.J., Barratt-Boyes S., Gambotto A. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 362:2003;1895-1896
10. So L.K., Lau A.C., Yam L.Y., Cheung T.M., Poon E., Yung R.W., Yuen K.Y. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet. 361:2003;1615-1617
11. Hon K.L., Leung C.W., Cheng W.T., Chan P.K., Chu W.C., Kwan Y.W., Li A.M., Fong N.C., Ng P.C., Chiu M.C., Li C.K., Tam J.S., Fok T.F. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet. 361:2003;1701-1703
12. Zhaori G. Antiviral treatment of SARS: can we draw any conclusions? C.M.A.J. 169:2003;1165-1166
13. Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., Walmsley S.L., Mazzulli T., Avendano M., Derkach P., Ephtimios I.E., Kitai I., Mederski B.D., Shadowitz S.B., Gold W.L., Hawryluck L.A., Rea E., Chenkin J.S., Cescon D.W., Poutanen S.M., Detsky A.S. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. Jama. 289:2003;2801-2809
14. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Treatment of SARS with human interferons. Lancet. 362:2003;293-294
15. Loutfy M.R., Blatt L.M., Siminovitch K.A., Ward S., Wolff B., Lho H., Pham D.H., Deif H., LaMere E.A., Chang M., Kain K.C., Farcas G.A., Ferguson P., Latchford M., Levy G., Dennis J.W., Lai E.K., Fish E.N. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Jama. 290:2003;3222-3228
16. Haagmans B.L., Kuiken T., Martina B.E., Fouchier R.A., Rimmelzwaan G.F., Van Amerongen G., Van Riel D., De Jong T., Itamura S., Chan K.H., Tashiro M., Osterhaus A.D. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 10:2004;290-293
17. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 361:2003;2045-2046
18. Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S., Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E., Ziebuhr J. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84:2003;2305-2315
19. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., Roper R.L. The genome sequence of the SARS-associated coronavirus. Science. 300:2003;1399-1404
20. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 300:2003;1394-1399
21. Lewis 2nd J.S., Terriff C.M., Coulston D.R., Garrison M.W. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin. Ther. 19:1997;187-214
22. Rizzardi G.P., Tambussi G., Bart P.A., Chapuis A.G., Lazzarin A., Pantaleo G. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. Aids. 14:2000;2257-2263
23. Kirk O., Lundgren J.D., Pedersen C., Mathiesen L.R., Nielsen H., Katzenstein T.L., Obel N., Gerstoft J. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. Antiviral Ther. 8:2003;595-602
24. Manfredi R., Calza L., Chiodo F. Prospective comparison of first-line nelfinavir therapy versus nelfinavir introduction in rescue antiretroviral regimens. AIDS Patient Care Stud. 17:2003;105-114
25. Fleury S., Rizzardi G.P., Chapuis A., Tambussi G., Knabenhans C., Simeoni E., Meuwly J.Y., Corpataux J.M., Lazzarin A., Miedema F., Pantaleo G. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA. 97:2000;5393-5398
26. Kaldor S.W., Kalish V.J., Davies 2nd J.F., Shetty B.V., Fritz J.E., Appelt K., Burgess J.A., Campanale K.M., Chirgadze N.Y., Clawson D.K., Dressman B.A., Hatch S.D., Khalil D.A., Kosa M.B., Lubbehusen P.P., Muesing M.A., Patick A.K., Reich S.H., Su K.S., Tatlock J.H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:1997;3979-3985